Frequency News and Research

RSS

Intellect obtains initial draft report of OXIGON Phase 1b clinical trial for Alzheimer’s disease

Intellect Neurosciences, Inc. a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has obtained an initial draft report of the Company's Phase 1b clinical trial for its lead Alzheimer's candidate, OXIGON (OX1).

27 Oct 2010

AZ-TMJ develops effective treatment for migraine headaches

AZ-TMJ is once again leading the way in innovative and effective treatments for severe cases of Temporomandibular Joint Disorders or TMD. AZ-TMJ has developed a variety of highly effective treatments to greatly reduce the frequency and severity of migraine headaches for a large percentage of sufferers. Approximately 16% to 17% of the population suffers from migraine headaches, which often have a debilitating effect on suffers' daily lives.

27 Oct 2010

New portable scanner for breast cancer diagnosis

Professor Zhipeng Wu has invented a portable scanner based on radio frequency technology, which is able to show in a second the presence of tumours malignant and benign in the breast on a computer.

From The University of Manchester 27 Oct 2010

Adherence to lifestyle recommendations reduces risk of colorectal cancer by 23%

Almost a quarter of colorectal (bowel) cancer cases could be prevented if people followed healthy lifestyle advice in five areas including diet and exercise, says a new study published on bmj.com today.

27 Oct 2010

Stereotactic radiation effective for trigeminal neuralgia

Stereotactic radiation is an effective, long-term treatment for trigeminal neuralgia: a painful condition that occurs with increased frequency in patients with multiple sclerosis (MS). Radiation is noninvasive and has less negative side effects than other treatments, according to the longest follow-up in a study of its kind presented October 31, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).

26 Oct 2010

Sleep disorders threaten kids with premature heart disease and stroke

Poor sleep patterns and lack of proper sleep could be threatening thousands of Canadian adolescents with premature heart disease and stroke, warns Heart and Stroke Foundation researcher Dr. Brian McCrindle, a pediatric cardiologist at the Hospital for Sick Children in Toronto.

26 Oct 2010

Vertex initiates OPTIMIZE Phase 3b study in patients infected with genotype 1 HCV

Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 3b study called OPTIMIZE that will evaluate twice-daily (BID) dosing of a telaprevir-based combination regimen in people chronically infected with genotype 1 hepatitis C virus (HCV) who have not been treated previously. This is the first Phase 3 study to evaluate twice-daily dosing of a protease inhibitor for the treatment of hepatitis C. OPTIMIZE will not include a control arm of pegylated-interferon and ribavirin alone.

26 Oct 2010

NovaBay delivers two poster presentations on Aganocide compounds at IDSA Annual Meeting

NovaBay Pharmaceuticals, Inc. a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, delivered two poster presentations on its compounds at the 48th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Vancouver, Canada.

25 Oct 2010

VTI expands into consumer electronics segment

VTI Technologies, a pioneer in Micro-Electro-Mechanical Systems (MEMS) for the past 20 years, is now taking a new direction and expanding into the consumer electronics segment. VTI is already the market leader in low-g sensors for the automotive industry, as well as in ultra-low power sensors for the medical implantable market.

25 Oct 2010

EES implantation reduces restenosis, repeat revascularization in patients with calcified culprit lesions

Two new studies have determined that everolimus-eluting stent (EES) implantation reduced the incidence of restenosis and repeat revascularization in patients with calcified culprit lesions, and had fewer clinical events. Results show the rate of major cardiac adverse events in EES-treated patients with calcified lesions were higher than in those for noncalcified lesions, but remained lower than the results of previously reported stent studies.

22 Oct 2010

Inspire presents data on denufosol therapy for cystic fibrosis at NACFC conference

Inspire Pharmaceuticals, Inc. announced today that data will be presented on denufosol tetrasodium, an investigational therapy for cystic fibrosis (CF), during oral and poster presentations at the 24th Annual North American Cystic Fibrosis Conference (NACFC) October 21-23, 2010 in Baltimore, Maryland.

22 Oct 2010

CIHR, RX&D - HRF to fund research projects on mental illness, palliative care

Six research projects on co-existing heath problems associated with mental illness and one project on palliative care among First Nations received over $9 million in funding announced today. This amount is provided by the Canadian Institutes of Health Research and the Rx&D Health Research Foundation.

22 Oct 2010

Nonprescription drug manufacturing and marketing costs increase: Kline

A number of costs associated with nonprescription drug manufacturing and marketing have increased over the past two and a half years. Certain material costs for plastic bottles and blister packs have risen by double digits during this time, increasing packaging expenses.

21 Oct 2010

UW Medicine patient receives implantable device for vestibular problems

A University of Washington Medical Center patient on Thursday, Oct. 21, will be the world's first recipient of a device that aims to quell the disabling vertigo associated with Meniere's disease.

21 Oct 2010

Annual conventional Pap smear is cost effective to reduce cancer incidence and mortality

A study of the options for reducing cancer incidence and mortality among women who have been treated for precancerous cervical lesions found that an annual conventional Pap smear is a cost effective strategy.

21 Oct 2010

A new way of seeing the world

Scientists at The Montreal Neurological Institute and Hospital - The Neuro, McGill University have discovered that our brains have the ability to determine the shape of an object simply by processing specially-coded sounds, without any visual or tactile input. Not only does this new research tell us about the plasticity of the brain and how it perceives the world around us, it also provides important new possibilities for aiding those who are blind or with impaired vision.

20 Oct 2010

$More studies needed on bisphosphonates therapy and fracture risk$

More studies needed on bisphosphonates therapy and fracture risk

On October 13, the Food and Drug Administration published a warning to doctors and patients about an increased risk of thigh fractures with a widely used group of bone-strengthening drugs called bisphosphonates. This warning was much awaited in the light of a report published in the American Journal of Bone and Mineral Research in September titled "Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Report of a Task Force of the American Society for Bone and Mineral Research."

20 Oct 2010

Microsulis tissue ablation systems presented at London meeting

Dr Peter Clegg, from the University of Bath microwave science team, who invented and developed the Microsulis microwave tissue ablation systems for destroying tumours, presented an overview of the success of this technology at the recent 'Changing Worlds Showcase Impact of University Research' meeting held in London.

20 Oct 2010

Cataract surgery also reduces car crashes

Cataract surgery not only improves vision and quality of life for older people, but is also apparently a way to reduce the number of car crashes. The research will be presented today's at the Scientific Program of the 2010 American Academy of Ophthalmology (AAO) - Middle East-Africa Council of Ophthalmology (MEACO) Joint Meeting.

20 Oct 2010

Dexamethasone improves quality of life after laparoscopic gallbladder surgery

A study presented at the American Society of Anesthesiologists 2010 Annual Meeting in San Diego seems to confirm that a single, small dose of the steroid dexamethasone improves the post-surgical quality of life of patients receiving laparoscopic gallbladder surgery.

20 Oct 2010